NAIER ANHARY: Open Payments
NPI 1689629552 · COLUMBIA, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$656 in 23 payments from 9 companies in 2025. Trend: 2023 $335 · 2024 $225 · 2025 $656
Food & beverage: $656
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 5 | $180 |
| Neurocrine BioSciences, Inc. | 5 | $157 |
| Lundbeck LLC | 3 | $78 |
| Vanda Pharmaceuticals Inc. | 2 | $74 |
| E.R. Squibb & Sons, L.L.C. | 3 | $51 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $25 |
Products named: INVEGA SUSTENNA, INGREZZA, FANAPT, REXULTI, COBENFY, ABILIFY ASIMTUFII, UZEDY, Auvelity.
Industry payments across MD — which companies pay providers there.
